Semaglutide is a GLP-1 analogue recently marketed in Belgium for the treatment of hyperglycaemia in patients with type 2 diabetes, by weekly subcutaneous administration. Among GLP-1 receptor agonists, semaglutide, at a maintenance dose of 0.5 or 1.0 mg/week, is currently the most effective compound for reducing chronic hyperglycaemia and body weight, as monotherapy or in combination with other hypoglycaemic medications, including basal insulin. The SUSTAIN 6 study also suggests a clinical benefit at the cardiovascular level. The tolerance and safety of semaglutide are comparable to those of other GLP-1 receptor agonists currently available in Belgium
Key Words
Semaglutide, glucagon-like peptide-1, type 2 diabetes, HbA1c, body weight, cardiovascular event